Why Oncologists Should Study Exceptional Responders Forbes According to results of a new study, a patient with advanced bladder cancer experienced a complete response for 14 months to the drug combination Everolimus and Pazopanib in a Phase I trial, and genomic profiling of his tumor revealed two unique ... |
